Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
Olutasidenib (FT-2102)治疗复发或难治性IDH1突变型胶质瘤患者：一项多中心、开放标签的Ib/II期试验
期刊:Neuro-Oncology
影响因子:13.4
doi:10.1093/neuonc/noac139
de la Fuente, Macarena I; Colman, Howard; Rosenthal, Mark; Van Tine, Brian A; Levacic, Danijela; Walbert, Tobias; Gan, Hui K; Vieito, Maria; Milhem, Mohammed M; Lipford, Kathryn; Forsyth, Sanjeev; Guichard, Sylvie M; Mikhailov, Yelena; Sedkov, Alexander; Brevard, Julie; Kelly, Patrick F; Mohamed, Hesham; Monga, Varun
